These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 31187690)

  • 1. Civic Engagement in California Cannabis Policy Development.
    Bowling C; Glantz SA
    J Psychoactive Drugs; 2019; 51(5):391-399. PubMed ID: 31187690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conflict of Interest Provisions in State Laws Governing Medical and Adult Use Cannabis.
    Bowling CM; Glantz SA
    Am J Public Health; 2019 Mar; 109(3):423-426. PubMed ID: 30676801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Cannabis Infringement Notice scheme in Western Australia: a review of policy, police and judicial perspectives.
    Sutton A; Hawks D
    Drug Alcohol Rev; 2005 Jul; 24(4):331-6. PubMed ID: 16234128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "Should I Buy or Should I Grow?" How drug policy institutions and drug market transaction costs shape the decision to self-supply with cannabis in the Netherlands and the Czech Republic.
    Belackova V; Maalsté N; Zabransky T; Grund JP
    Int J Drug Policy; 2015 Mar; 26(3):296-310. PubMed ID: 25655217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Costs of cannabis testing compliance: Assessing mandatory testing in the California cannabis market.
    Valdes-Donoso P; Sumner DA; Goldstein R
    PLoS One; 2020; 15(4):e0232041. PubMed ID: 32324781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Compliance With Cannabis Act Regulations Regarding Online Promotion Among Canadian Commercial Cannabis-Licensed Firms.
    Sheikhan NY; Pinto AM; Nowak DA; Abolhassani F; Lefebvre P; Duh MS; Witek TJ
    JAMA Netw Open; 2021 Jul; 4(7):e2116551. PubMed ID: 34251442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A critique of cannabis legalization proposals in Canada.
    Kalant H
    Int J Drug Policy; 2016 Aug; 34():5-10. PubMed ID: 27292414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The great cannabis classification debacle: what are the likely consequences for policing cannabis possession offences in England and Wales?
    Turnbull PJ
    Drug Alcohol Rev; 2009 Mar; 28(2):202-9. PubMed ID: 19320707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The case for small-scale domestic cannabis cultivation.
    Decorte T
    Int J Drug Policy; 2010 Jul; 21(4):271-5. PubMed ID: 20176465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Making residential cannabis growing operations actionable: a critical policy analysis.
    Carter C
    Int J Drug Policy; 2009 Jul; 20(4):371-6. PubMed ID: 19111455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Moral regulation and the presumption of guilt in Health Canada's medical cannabis policy and practice.
    Lucas P
    Int J Drug Policy; 2009 Jul; 20(4):296-303. PubMed ID: 19124233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging prospects for non-medical cannabis legalisation in New Zealand: An initial view and contextualization.
    Fischer B; Bullen C
    Int J Drug Policy; 2020 Feb; 76():102632. PubMed ID: 31864106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Behind Schedule - Reconciling Federal and State Marijuana Policy.
    Haffajee RL; MacCoun RJ; Mello MM
    N Engl J Med; 2018 Aug; 379(6):501-504. PubMed ID: 29996065
    [No Abstract]   [Full Text] [Related]  

  • 14. An economic analysis of different cannabis decriminalization scenarios.
    Ogrodnik M; Kopp P; Bongaerts X; Tecco JM
    Psychiatr Danub; 2015 Sep; 27 Suppl 1():S309-14. PubMed ID: 26417786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulating Cannabis Manufacturing: Applying Public Health Best Practices from Tobacco Control.
    Orenstein DG; Glantz SA
    J Psychoactive Drugs; 2018; 50(1):19-32. PubMed ID: 29438634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Creating the cannabis user: a post-structuralist analysis of the re-classification of cannabis in the United Kingdom (2004-2005).
    Acevedo B
    Int J Drug Policy; 2007 May; 18(3):177-86. PubMed ID: 17689364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early-Stage Cannabis Regulatory Policy Planning Across Canada's Four Largest Provinces: A Descriptive Overview.
    Watson TM; Hyshka E; Bonato S; Rueda S
    Subst Use Misuse; 2019; 54(10):1691-1704. PubMed ID: 31076006
    [No Abstract]   [Full Text] [Related]  

  • 18. Medicare program; revisions to payment policies under the physician fee schedule for calendar year 2003 and inclusion of registered nurses in the personnel provision of the critical access hospital emergency services requirement for frontier areas and remote locations. Final rule with comment period.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2002 Dec; 67(251):79965-80184. PubMed ID: 12510665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-medical cannabis in North America: an overview of regulatory approaches.
    Lancione S; Wade K; Windle SB; Filion KB; Thombs BD; Eisenberg MJ
    Public Health; 2020 Jan; 178():7-14. PubMed ID: 31600630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Equity in Coverage of Local Cannabis Control Policies in California, 2020‒2021.
    Matthay EC; Mousli LM; Fu C; Zhang S; Ponicki WR; Gruenewald P; Apollonio DE; Schmidt LA
    Am J Public Health; 2022 Nov; 112(11):1640-1650. PubMed ID: 36075009
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.